Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment ... ( PITTSBURGH July 16 ...)

Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)

Date:7/16/2009

PITTSBURGH, July 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

Liothyronine Sodium Tablets are the generic version of King Pharmaceuticals' thyroid deficiency treatment Cytomel(R), which had total U.S. sales of approximately $54 million for the 12 months ending March 31 for the same strengths, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 120 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:6/18/2013)... shown that cancer cells have a much different ... scientists at The University of Texas at Dallas have ... strategy to combat lung cancer. , In an article ... ONE , UT Dallas researchers compared the metabolic characteristics ... taken from the same patient. , They found ...

(Date:6/18/2013)... new commercial venture, using technology developed at Case ... and Case School of Engineering, has made available ... allows graduate students and others training to evaluate ... program, reducing stress on the trainee, because a ... real person. , Graduate students studying to ...

(Date:6/18/2013)... June 18, 2013 More than 1.1 million ... with HIV/AIDS, according to the Centers for Disease Control and ... are infected. In support of National HIV Testing Day on ... Disability Insurance (SSDI) representation, the CDC and other organizations ... , The CDC reports about 50,000 new HIV infections each ...

(Date:6/18/2013)... 2013 The Elizabeth Glaser Pediatric AIDS ... the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) ... new milestones in the global effort to eliminate pediatric ... that as of June 2013, one million babies globally ... Since PEPFAR’s inception in 2003, EGPAF has been a ...

(Date:6/18/2013)... 2013 Two months ago, Suyima Torres, 28, ... for a second session of a silicone treatment for gluteus ... treatment was allegedly performed by a mystery Venezuelan doctor in ... According to Dr. Bernabe Vazquez of Bayshore Cosmetic Surgery ... from doctor’s who are not board certified is more common ...

Breaking Medicine News(10 mins):Health News:UT Dallas study suggests new approach to fight lung cancer 2 Health News:UT Dallas study suggests new approach to fight lung cancer 3 Health News:SimuCase avatars advance speech-language pathology training 2 Health News:Allsup Observes National HIV Testing Day June 27 2 Health News:Allsup Observes National HIV Testing Day June 27 3 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2 Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3 Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2 Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3

[0] UT Dallas study suggests new approach to fight lung cancer [0] SimuCase avatars advance speech-language pathology training [0] Allsup Observes National HIV Testing Day June 27 [0] One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS [0] Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection

... the first FDA approval of a PEGylated Fab, fragment of ... humanized ... Food and,Drug Administration (FDA) approved UCB,s Cimzia(R) (certolizumab pegol) for,reducing ... in adult patients with moderate to severe active disease who ...

... PALO ALTO, Calif., April 23 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... in Key Biscayne, FL,on May 1, 2008 at ... of the presentation may be accessed by visiting ...

... Information Technology to Meet Today,s Healthcare Challenges, ... Quantum Group,Inc. (AMEX: QGP, QGP.WSA, QGP.WSB) ... CEO, Noel J. Guillama has been asked ... Corporation,s 7th Annual Life,Science Conference, "Leveraging Information ...

... - Treat Yourself to EDY,S Winning American Idol Ice Cream and, Limited-edition ... ... Cause -, BOSTON, and OAKLAND, Calif., April 23 Everyone,s a,winner ... Day on Saturday, May 3 for the Triple Winner Game,Scoop(R) Day event., ...

... increased 18% to $1.09; ... fiscal year, FRANKLIN LAKES, N.J., April 23 ... reported record quarterly revenues,of $1.747 billion for the second ... 11 percent over the prior year period. This,quarter,s revenue ...

... Superior court dismisses illegal temporary restraining order ... publicity stunt, OAKLAND, Calif., April 22 ... order against the,Service Employees International Union (SEIU) and ... publicity stunt by the California Nurses Association,(CNA). The ...

FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform Jazz Pharmaceuticals to Present at Morgan Stanley Conference The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference EDY'S(R) Slow Churned(R) and Stop & Shop Stores Announce Scoop Day With Sweet Deals to Support the Fight Against Childhood Cancer BD Announces Results for Second Fiscal Quarter Court Throws Out Restraining Order Against SEIU

(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...

(Date:6/18/2013)... MINNEAPOLIS , June 18, 2013 ... while being highly portable and lightweight. Simultaneously, circuitry ... and the processing speed to which it performs ... both medical electronics and military equipment, such as ... lightweight. Omnetics, micro-circular and nano-circular connectors include custom ...

(Date:6/18/2013)... SYDNEY, Australia And EMERYVILLE, ... Adamas Pharmaceuticals, Inc. presented final results today from ... HCl extended release) capsules demonstrating a statistically significant ... change from baseline at week 8 versus placebo ... is Adamas, investigational extended-release formulation of amantadine intended ...

Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2 Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3 Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6

[0] Decision Resources' Market Access Tracker Now Covers the Middle East and Africa [0] Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility [0] Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease

... Susquehanna Financial Group, LLLP (SFG), the institutional broker-dealer member ... that Gary Nachman has joined the firm as ... whose coverage will include names such as Allergan, Cephalon, ... Chilcott , will be based out of SFG,s New ...

... July 20 Pittsburgh -based Foundation Radiology ... is proud to announce its strategic partnership with Acusis, a national ... practices. , , ... Headquartered in Pittsburgh , Acusis delivers healthcare solutions that are ...

Cached Medicine Technology:Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector 2 Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector 3 Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 2 Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis 3

Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector Foundation Radiology Group Forms Strategic Partnership with Transcription Experts, Acusis

... Quant™ 200 is a fixed wavelength ... 460 nm emission. The spectral characteristics ... of double-stranded DNA using the standard ... minimizes interference from the presence of ...

The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....

Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...

... neonate/pediatric blanket provides warmth to ... The blanket may be used ... with a drape that is ... patient to help retain heat. ...

Medicine Products:

DyNA Quant™ 200 Fluorometer VICTOR² D fluorometer LDL Cholesterol, Direct Test FilteredFlo® Neonate/Pediatric Warming Blanket